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Summary Integrated backscatter intravascular ultrasound (IB-IVUS) capable of assess-
ing plaque properties has recently become clinically applicable. We observed short-term
atorvastatin-induced changes in coronary arterial plaque properties using IB-IVUS. The patient
was a 57-year-old man who underwent coronary angiography when admitted to our hospital for
cerebrovascular surgery, and lesions were observed in 2 branches: 99% and 90% stenoses in the
proximal anterior descending branch (LAD) and middle region of the circumﬂex, respectively.
Stenting was performed for the LAD on November 4, 2009 and for the circumﬂex on Decem-
ber 9. Oral atorvastatin administration at 10mg/day was initiated on November 5 because the
LDL-cholesterol level was high (160mg/dl). A region about 5mm in length proximal to the stent
placed in the LAD was analyzed using IB-IVUS. Atorvastatin lowered the LDL cholesterol level
from 160 to 79mg/dl. On IB image analysis, although the period was as short as about 1 month,
a marked decrease in the fatty component (44%→ 26%) and an increase in the ﬁbrous compo-
nent (53%→ 66%) were observed in the plaque. It was suggested that atorvastatin changes the
tissue properties of coronary arterial plaques from a very early phase. It might be associated
with the stabilization of coronar
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coenzyme A reductase activity. Since the ﬁrst statin was
discovered by Japanese researchers in 1973, various types
of statin have been developed and used as therapeutic
Table 1 Changes in laboratory proﬁles.
Baseline
(4th
November)
Follow-up
(9th
December)
HDL cholesterol (mg/dl) 41 36
LDL cholesterol (mg/dl) 160 79112
ntroduction
s clinical outcomes of cholesterol-lowering therapy in
apanese have recently been accumulated, the importance
f the vascular plaque-stabilizing as well as lipid level-
owering effects of statins has been attracting attention.
ntravascular ultrasound (IVUS) is available for evaluating
laques in the coronary artery, but accurate qualitative
valuation of plaques in conventional gray-scale images has
een difﬁcult. Integrated backscatter (IB)-IVUS has recently
ecome clinically applicable, in which the plaque properties
an be diagnosed into 4 types by combining spectral parame-
ers of posterior scattering signals of IVUS: lipid pool, dense
brosis, ﬁbrosis, or calciﬁcation. In this study, we observed
hort-term atorvastatin-induced changes in the properties
f coronary arterial plaques using IB-IVUS in a patient.
ase report
n September 2009, a 57-year-old man who was a past
moker with a history of borderline diabetes, hyperlipi-
emia, and hypertension was admitted to the neurosurgery
epartment of our hospital for close examination and treat-
ent for severe stenosis in the left middle cerebral artery.
ince there were many risk factors, the patient was referred
o our department and coronary angiography was per-
ormed. Lesions were observed in 2 branches: 99% and
0% stenoses in the proximal anterior descending branch
LAD) and middle region of the circumﬂex, respectively.
n November 4, 2009, a DRIVER stent (3.0mm× 20mm,
edtronic Vascular Inc., Santa Rosa, CA, USA) was placed for
he lesion in the LAD, and plaque of about 5mm in length was
valuated at a site 5mm from the proximal end of the placed
tent using IB-IVUS. For IVUS, Atlantis (40MHz) (Boston Sci-
ntiﬁc Corporation/Cardiovascular System Inc., San Jose,
A, USA) was used. Data were collected at a 0.5-mm/s auto
ullback and analyzed using IVUS console (Galaxy, Boston
cientiﬁc Corporation/Cardiovascular System Inc.). Since
yperlipidemia was detected on blood testing on admission
low-density lipoprotein cholesterol (LDL-C), 160mg/dl;
riglyceride (TG), 98mg/dl; high-density lipoprotein choles-
Figure 1 Clinical course. IB-IVUS, integrateK. Yamaguchi et al.
erol (HDL-C), 41mg/dl], oral atorvastatin administration
as initiated at 10mg/day on the day following surgery
Fig. 1). The patient was readmitted in December 2009
or coronary intervention for the lesion in the circumﬂex.
n blood testing, LDL-C, TG, and HDL-C were lowered to
9mg/dl, 82mg/dl, and 36mg/dl, respectively (Table 1).
he lesion proximal to the stent placed in the LAD was re-
valuated using IB-IVUS before stenting. The components
n the central, middle, and peripheral regions assumed to
e the same lesion based on the distance from the stent
nd were also evaluated, and a marked reduction of the
lue area and an increase in the green area were visually
bserved (Fig. 2). The percent volume of each plaque com-
onent in the analytical region was also investigated. The
ercent volumes of the fatty (lipid pool) and ﬁbrous (ﬁbro-
is) components changed from 44% to 26% and from 53%
o 66% (Table 2), respectively, showing stabilization of the
laque. The total plaque volumewas slightly decreased from
3.8mm3 to 32.5mm3 (Table 2).
iscussion
tatins comprise a group of drugs lowering the blood
holesterol level by inhibiting 3-hydroxy-3-methylglutaryl-Triglycerides (mg/dl) 98 82
C-reactive protein (mg/dl) 0.25 0.18
Hemoglobin A1c (%) 5.4 5.5
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
d backscatter intravascular ultrasound.
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characterization. The lesion which is masked by acoustic
shadowing, might be misinterpreted as lipid pool. Second,
thrombus has several IB values according to its formation.
Table 2 Changes in lesion characteristics and IB
parameters.
Baseline
(4th
November)
Follow-up
(9th
December)
Plaque volume (mm3) 33.8 32.5
Mean vessel area (mm2) 14.3± 1.3 13.4± 1.0
Mean lumen area (mm2) 7.5± 1.5 6.9± 1.1
Fibrosis volume (mm3) 18 (53%) 22 (66%)
Lipid pool volume (mm3) 15 (44%) 8 (26%)
Dense ﬁbrosis volume (mm3) 0.7 (2.6%) 2.2 (6.7%)Figure 2 Typical changes in IB images. (A) Distal area at 5.5m
the proximal end of the stent. (C) Proximal area at 9.0mm from
drugs for hypercholesterolemia worldwide. It has been pro-
posed that the reduction of coronary events by active
lipid-lowering treatment using drugs, such as statins, is due
to the qualitative or functional improvement of plaques [1].
In the Reversal of Atherosclerosis with Lipitor (REVER-
SAL) study reported in 2004, the LDL-C level was moderately
reduced by pravastatin or aggressively reduced by atorvas-
tatin, and changes in the plaque volume on IVUS after 6
months were compared between the 2 groups. The LDL-C
level was reduced by 25.2% from 150 to 110mg/dl on average
in the pravastatin group and by 46.3% from 150 to 79mg/dl
on average in the atorvastatin group. The plaque volume
increased by 2.7% in the pravastatin group, but decreased
by 0.4% in the atorvastatin group. These ﬁndings suggested
that an increase in the plaque mass can be inhibited by
lowering the LDL-C level to about 80mg/dl [2]. The GAIN
Study reported that the composition of plaques may change
based on an increase in the echo brightness of plaques on
IVUS, showing that statins may stabilize unstable plaques
[3]. The stabilization of plaque was also observed in the IB-
IVUS image in this patient, suggesting that the pleiotropic
effect of statins centering on the anti-inﬂammatory effect
plays an important role.
IB-IVUS has recently become clinically applicable, in
which plaque properties can be diagnosed by combining
spectral parameters of posterior scattering signals of IVUS
[4]. Kawasaki et al. divided 52 stable angina pectoris
patients with hyperlipidemia into 3 groups: atorvastatin
(20mg/day) and pravastatin (20mg/day) treatment groups,
and a control group (dietary therapy), and the plaque prop-
erties were evaluated using IB-IVUS during percutaneous
coronary arterioplasty and after 6 months. It was demon-om the proximal end of the stent. (B) Mid area at 7.0mm from
proximal end of the stent. IB, integrated backscatter.
trated within a short 6-month period that lipid-lowering
herapy stabilized plaques by reducing the fatty component
nd increasing the ﬁbrous component in fatty component-
ich plaques [5]. Large-scale clinical studies reported that
laques shrank after statin administration for 6 months
o 3 years [2,3,6—8], but changes in the tissue properties
ay have occurred very early within about 1 month in this
atient, showing that early statin administration is effective
or stabilizing coronary arterial plaques.
There are several limitations of the current study. First,
coustic shadowing by a guide wire may affect tissueCalciﬁcation volume (mm3) 0.1 (0.4%) 0.4 (1.3%)
Mean area: mean value± standard deviation. IB, integrated
backscatter.
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resh thrombus and lipid pool have similar IB values and
rganized thrombus and ﬁbrosis also have similar IB values.
t is possible that fresh thrombus at baseline was misclassi-
ed as lipid-pool (blue) and organized thrombus at follow-up
s ﬁbrosis (green). This is a limitation of analyses using IB-
VUS. Third, it is possible that other medications which had
een initiated before, contributed to the change in plaque
omposition. However, atorvastatin was the only drug which
ad been added after the ﬁrst IB-IVUS. Therefore, the
torvastatin might play the most important role in the
hanges.
In conclusion, short-term atorvastatin-induced changes
n the coronary arterial plaque properties were observed
sing IB-IVUS in a patient. It was suggested that IB-
VUS is useful for short-term course observation during
ipid-lowering therapy, and atorvastatin changes the tissue
roperties of coronary arterial plaques from a very early
hase. It might be associated with the stabilization of coro-
ary plaque.
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